Literature DB >> 30797639

Differential durability of immune responses to measles and mumps following MMR vaccination.

Richard B Kennedy1, Inna G Ovsyannikova2, Antonia Thomas3, Beth R Larrabee4, Steven Rubin3, Gregory A Poland2.   

Abstract

The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Cell-mediated immunity; Humoral immunity; MMR-II vaccine; Measles; Measles vaccine; Measles virus; Mumps; Mumps vaccine; Mumps virus; T cell ELISPOT

Year:  2019        PMID: 30797639      PMCID: PMC6414234          DOI: 10.1016/j.vaccine.2019.02.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

1.  Assay of humoral immunity to mumps virus.

Authors:  P A Pipkin; M A Afzal; A B Heath; P D Minor
Journal:  J Virol Methods       Date:  1999-05       Impact factor: 2.014

2.  Effect of multiple freeze-thaw cycles on detection of measles, mumps, and rubella virus antibodies.

Authors:  Norman A Pinsky; Jeanne M Huddleston; Robert M Jacobson; Peter C Wollan; Gregory A Poland
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

3.  Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps.

Authors:  T Harmsen; M C Jongerius; C W van der Zwan; A D Plantinga; C A Kraaijeveld; G A Berbers
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 4.  The molecular epidemiology of mumps virus.

Authors:  Kathrin Mühlemann
Journal:  Infect Genet Evol       Date:  2004-09       Impact factor: 3.342

5.  Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination.

Authors:  Bernard J Cohen; Susette Audet; Nick Andrews; Judy Beeler
Journal:  Vaccine       Date:  2007-11-12       Impact factor: 3.641

6.  Immunological relationships between parainfluenza virus type 4 and other paramyxoviruses studied by use of monoclonal antibodies.

Authors:  H Komada; E Klippmark; C Orvell; R E Randall; Y Ito; E Norrby
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

7.  Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.

Authors:  Steven A Rubin; Li Qi; Susette A Audet; Bradley Sullivan; Kathryn M Carbone; William J Bellini; Paul A Rota; Lev Sirota; Judy Beeler
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

8.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

9.  Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2008-05-07

10.  Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.

Authors:  Anand A Date; Moe H Kyaw; Alison M Rue; Julie Klahn; Leann Obrecht; Terry Krohn; Josh Rowland; Steve Rubin; Thomas J Safranek; William J Bellini; Gustavo H Dayan
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 7.759

View more
  17 in total

Review 1.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

2.  Mumps virus-specific immune response outcomes and sex-based differences in a cohort of healthy adolescents.

Authors:  Marguerite M Riggenbach; Iana H Haralambieva; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland; Richard B Kennedy
Journal:  Clin Immunol       Date:  2021-12-28       Impact factor: 3.969

Review 3.  Moving beyond Titers.

Authors:  Benjamin D Brooks; Alexander Beland; Gabriel Aguero; Nicholas Taylor; Francina D Towne
Journal:  Vaccines (Basel)       Date:  2022-04-26

4.  Durability of humoral immune responses to rubella following MMR vaccination.

Authors:  Stephen N Crooke; Marguerite M Riggenbach; Inna G Ovsyannikova; Nathaniel D Warner; Min-Hsin Chen; Lijuan Hao; Joseph P Icenogle; Gregory A Poland; Richard B Kennedy
Journal:  Vaccine       Date:  2020-11-12       Impact factor: 3.641

5.  Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy.

Authors:  Gabriele Anichini; Claudia Gandolfo; Simonetta Fabrizi; Giovan Battista Miceli; Chiara Terrosi; Gianni Gori Savellini; Shibily Prathyumnan; Daniela Orsi; Giuseppe Battista; Maria Grazia Cusi
Journal:  Vaccines (Basel)       Date:  2020-02-03

6.  Measles seroprevalence among healthcare workers in South Korea during the post-elimination period.

Authors:  Seung Beom Han; Sun Hee Park; Yunmi Yi; Seul Ki Ji; So Hee Jang; Min Hee Park; Ji Eun Lee; Hye Sook Jeong; Soyoung Shin
Journal:  Hum Vaccin Immunother       Date:  2021-03-09       Impact factor: 3.452

Review 7.  Current Challenges in Vaccinology.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Peter Palese; Gregory A Poland
Journal:  Front Immunol       Date:  2020-06-25       Impact factor: 7.561

8.  A Survey of Vaccine-Induced Measles IgG Antibody Titer to Verify Temporal Changes in Response to Measles Vaccination in Young Adults.

Authors:  Hiraku Sasaki; Tomoko Fukunaga; Ai Asano; Yoshio Suzuki; Yuko Nakanishi; Junzi Kondo; Hiroki Ishikawa; Nobuto Shibata
Journal:  Vaccines (Basel)       Date:  2019-09-19

9.  Seroprevalence of IgG antibodies against measles in a selected Polish population - do we need to be re-vaccinated?

Authors:  Justyna Holka; Katarzyna Pawlak; Olga Ciepiela
Journal:  Cent Eur J Immunol       Date:  2020-01-20       Impact factor: 2.085

10.  Measles and mumps outbreaks in Lebanon: trends and links.

Authors:  Talal El Zarif; Mohamed Faisal Kassir; Nazih Bizri; Ghida Kassir; Umayya Musharrafieh; Abdul Rahman Bizri
Journal:  BMC Infect Dis       Date:  2020-03-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.